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Abstract
One of the concerns of using sentinel node biopsy (SNB) is the
risks of a false-negative result (FNR). We have created a
mathematical model to estimate the effects of FNR on mortality
because of excess local recurrence and adjuvant therapy
inappropriately withheld. With a FNR of 9.7%, the absolute effect
on 10-year mortality is estimated to be less than 0.6% for all
patients with tumours <2 cm in size. Since the impact of FNR on
mortality is small and FNR rates do not improve with training, we
suggest that detection rate alone is an adequate criterion for
judging competence in SNB.
Introduction
Sentinel node biopsy (SNB) is being adopted as a standard of
care for breast cancer amidst concerns about the effect of a
false-negative result. A high false-negative rate (FNR) could be
harmful because of axillary relapse or a missed opportunity to
institute systemic adjuvant therapy. There appears to be a
general consensus that it is extremely important to achieve a
low FNR by adequate training. We modelled the local and
systemic effect of not treating a falsely negative axilla (Table 1).
Method
We used the false negative rate (FNR; specifically the
proportion of true positives missed by SNB) of 9.7%
obtained in the NSABP B-32 trial [1] and estimated the node
positivity from Surveillance, Epidemiology, and End Results
(SEER) data [2]. We used Adjuvant! software [3] to estimate
the benefit of adjuvant systemic chemotherapy for oestrogen
receptor (ER)-negative patients. This would be similar to the
additional benefit of chemotherapy for ER-positive patients on
top of hormone therapy. The absolute number of patients with
a falsely negative axilla is the product of the estimated node
positivity and the FNR (AFN = estimate node positivity × FNR).
To calculate the effect of the lost opportunity to institute
adjuvant systemic therapy, we multiplied the estimated
number of patients with a falsely negative axilla (AFN) by the
difference between the benefit from treating node-positive
and node-negative patients (AFN × [NP – NN]). To calculate
the effect of leaving axillary disease untreated, we estimated
(NSABP B-04 [4]) that 50% of involved nodes cause local
recurrence at 10 years and that about a fifth of this translates
into mortality [5]. This would be equal to AFN × 0.1.
Unsuspected harm from a falsely negative axilla is calculated
by adding the increased mortality from axillary recurrence to
the effect of a lost opportunity to institute adjuvant systemic
chemotherapy for those women with false-negative axilla, and
the resulting values are shown in Table 1.
In this model, it is assumed that patients with tumours larger
than 2 cm will receive adjuvant systemic therapy anyway and
hence are not shown. The bottom rows of Table 1 show the
effect of a 100% FNR, which simulates the effect of not
doing any axillary staging. These values could be used during
discussions with patients to illustrate the benefit, or lack
thereof, of treating the axilla in these patients with good
prognosis.
Results
Let us assume that SNB is negative. To use the model, first
look up the figures in row 3 and decide whether the benefit in
node-negative women is sufficient to recommend chemo-
therapy. If the patient will be receiving chemotherapy anyway,
then look at row 8, 12, or 16 to see the estimated harm from
a false-positive SNB for FNRs of 9.7%, 20% and 100%,
respectively. If your decision is not to recommend chemo-
therapy because the potential benefit from chemotherapy in
node-negative women (in row 3) is too small, then look at
rows 10, 14 and 18 to see the unsuspected harm that would
come to the patient because of a falsely negative SNB. Now
add the values in row 3 to those in row 10, 14, or 18 to
estimate the total harm that may come to a patient who is
SNB negative and is not given chemotherapy, and see
whether this is enough to tip the balance in favour of
recommending chemotherapy.
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In each of these examples, these decisions could even be
made before surgery. If the harm from a 100% FNR (row 18)
is acceptable, then the axilla need not even be touched.
Conclusion
This mathematical model could be used in day-to-day
decision making in joint consultation with the patient. The
values generated are absolute values and relate to the very
patients who would be considered the best candidates for
SNB, and therefore are easier to discuss with patients than
hazard ratios or relative risks. Table 1 can be used to vary the
FNRs and even the benefit from chemotherapy when results
of newer drug trials become available. The expanded Excel
version is available from the authors.
The fact that the FNR does not reduce with increasing
experience raises a fundamental biological doubt over the
mechanistic model of lymphatic spread on which SNB is
based. It is likely that in 10% of patients tumour cells truly
skip the sentinel node, just as blood-borne metastases that
travel via the veins frequently skip the lungs. If we wish to
identify accurately and treat axillary spread, then we must find
methods based on newer biological markers, perhaps in
combination with functional imaging, to identify these patients
better. Until then, each patient must participate in informed
decision making about whether and when SNB is to be used as
a definitive treatment, with discussion about its absolute risks.
On an allied issue, nationwide studies [1,6] have found that
training improves the detection rate but does not reduce the
FNR. This model suggests that in absolute terms a FNR has a
small impact on mortality. Thus, it seems prudent to use only
the ‘detection rate’ in judging competence in SNB, avoiding
the validation phase with concurrent axillary dissection.
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